Currently submitted to: JMIR Preprints
Date Submitted: Aug 29, 2022
Open Peer Review Period: Jan 20, 2023 - Mar 20, 2023
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Research Into Potential Therapies Against COVID-19, With Focus On Ivermectin
ABSTRACT
Purpose: Ivermectin is a broad-spectrum antiparasitic and an effective drug to treat COVID-19. In this article, we looked at the effects of ivermectin on coronavirus and its patients in three ways. We have discussed and organized other previously discovered potential therapies and reviewed them in Table 2 and in the last section.
Methods:
We searched for articles on MedRxiv, PubMed, Google Scholar, MEDLINE, EMBASE uses the appropriate search terms. ClinicalTrials.gov was searched for available clinical trials evaluating the effectiveness of ivermectin. We also use EU clinical trial registry data and ANZ registry data for clinical trials. Also, we performed our methods in 4 stages: Identifying studies, Selection of Studies, Collating Studies, Reporting results.
Results:
Results are variable. Some studies have shown the effectiveness of ivermectin, others have not. Furthermore, some studies show that a combination of ivermectin with other drugs is useful. Conclusion: Overall, we believe the reason ivermectin is useful is that it goes back to its origin, which is soil. Our theory and hypothesis is that if the coronavirus, created by man or by nature, can generally be treated with nature, that is, the soil. The interesting thing is that today we know that ivermectin is effective in the fight against the coronavirus. In fact, other drugs like teicoplanin, cyclosporine and rapamycin that are effective against the coronavirus have come from the soil. We hope that this article has been able to take a step in finding a corona drug, InshaAllah.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.